title: Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons.
abstract: Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml.
authors: Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA jameswkeck@gmail.com bdm9@cdc.gov.
authors: James W
authors: JW
authors: Keck
authors: Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.
authors: Lisa R
authors: LR
authors: Bulkow
authors: Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.
authors: Gregory A
authors: GA
authors: Raczniak
authors: Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA.
authors: Susan E
authors: SE
authors: Negus
authors: Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.
authors: Carolyn L
authors: CL
authors: Zanis
authors: Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.
authors: Michael G
authors: MG
authors: Bruce
authors: Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors: Philip R
authors: PR
authors: Spradling
authors: Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors: Eyasu H
authors: EH
authors: Teshale
authors: Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA jameswkeck@gmail.com bdm9@cdc.gov.
authors: Brian J
authors: BJ
authors: McMahon
mesh_terms: D000293:Adolescent; D000328:Adult; D000413:Alaska; D002648:Child; D002675:Child, Preschool; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D044382:Population Groups; D013997:Time Factors
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines